Objective: This study was aimed to explore whether the omentin-1, a novel adipokine marker, could be a biomarker for stroke, as well as its association with stroke severity.
Methods: This study included 239 patients with ischemic stroke. The serum omentin-1 level was determined and the stroke was evaluated when the patients were hospitalized. The control groups consisted of 108 patients with matched age, gender and prior vascular risk factors and 120 health control with matched age and gender. The stroke severity was assessed with National Institutes of Health Stroke Scale (NIHSS) when the patients were hospitalized, and NIHSS score > 6 was evaluated as moderate-to-severe stroke.
Results: Omentin-1 level in serum samples of 239 stroke patients was determined, with the median value of 109.5 ng/ml [Inter Quartile Range (IQR), 78.4-142.9 ng/ml]. There was a negative relation between omentin-1 level and the infarct volume (r = -0.289, P = 0.001). The level of omentin-1 was significantly reduced in stroke patients than that of in control group 1 [125.3 (IQR, 95.8-158.7); P = 0.002] and control group 2 [146.5 (IQR, 116.2-177.3); P < 0.001]. With the analysis of multivariate model, omentin-1 as a continuous variable was related to lowered stroke risk (odds ratios [OR] 0.994, 95% confidence interval (CI): 0.990-0.998; P = 0.006). In addition, omentin-1 was an independent indicator for stroke severity (OR 0.992, 95% CI: 0.989-0.996). Levels of omentin-1 in the Q1 showed a relative risk of 2.66 (95% CI: 1.52-4.18) for moderate-to-severe stroke after adjusting for above possible confounders compared to reference category [Quartile (Q): 2-4].
Conclusion: The data indicated a negative relation between omentin-1 level and risk of ischemic stroke. The omentin-1 could be promising indicator of stroke and its severity.
Keywords: Adipokine; Clinical severity; Infarct volume; Ischemic stroke; Omentin-1; Risk.
Copyright © 2018 Elsevier Ltd. All rights reserved.